STOCK TITAN

Becton Dickinson & Co - BDX STOCK NEWS

Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.

Becton, Dickinson and Company (NYSE: BDX) is a global leader in medical technology driving advancements in healthcare through innovative devices, diagnostic solutions, and clinical systems. This page provides real-time updates on BD's latest developments, offering investors and professionals a centralized hub for tracking corporate announcements and industry impact.

Access authoritative information including earnings reports, regulatory milestones, product innovations, and strategic partnerships. Our curated news collection helps stakeholders monitor BD's contributions to medication management, diagnostic testing, and surgical care across 190+ countries.

Key updates cover BD Medical safety-engineered products, BD Life Sciences diagnostic platforms, and BD Interventional surgical technologies. Stay informed about developments in smart medication systems, infectious disease testing, and minimally invasive procedures shaping modern healthcare.

Bookmark this page for ongoing insights into BD's operational updates, leadership changes, and R&D breakthroughs. Verify critical information directly through primary sources while maintaining awareness of market trends in the $600B+ medical technology sector.

Rhea-AI Summary

BD (Becton, Dickinson and Company) announced a study showing the BD Veritor™ System for Rapid Detection of SARS-CoV-2 is as effective as the Quidel Sofia 2 SARS Antigen Fluorescent Immunoassay. The research involved 361 patient samples, indicating a high agreement in testing accuracy. The BD Veritor™ Plus system showed better correlation with PCR results than its competitor. The study aims to assess performance in community settings and highlights the importance of various factors in understanding antigen assay performance. The findings support the rapid antigen tests' utility in managing COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
covid-19
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) (NYSE:BDX) announced its participation in upcoming virtual investor healthcare conferences. The company will present at the Wells Fargo Securities 2020 Healthcare Conference on September 10, 2020, at 8:40 a.m. EDT, and the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 8:45 a.m. EDT. Webcasts of these presentations will be available on their corporate website and can be replayed for seven days post-conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
conferences
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) has updated its voluntary recall of the BD Alaris™ System due to hardware issues. The U.S. FDA has classified three of the situations as Class I recalls, indicating a high probability of serious health risks or death, while one situation is a Class II recall. The issues include damaged connectors and battery problems that may impact device operation. BD has provided corrective instructions to affected customers, emphasizing the importance of safety in medical technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
Rhea-AI Summary

BD (Becton, Dickinson and Company) announced the appointment of Kristen Stewart as the senior vice president of Strategy and Investor Relations, effective Aug. 31, 2020. Stewart brings nearly two decades of experience in the medical technology sector, having previously led research at Barclays Capital. Her role will focus on enhancing shareholder value and communicating BD's long-term growth strategy. Tom Polen, CEO of BD, expressed confidence in her strategic skills, while Christopher Reidy, CFO, noted her strong investment community ties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
none
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) will present at the UBS Genomics 2.0 and MedTech Innovations Virtual Summit on August 13, 2020, at 3:30 p.m. ET. A live webcast of the presentation will be available on the BD corporate website and can be replayed until August 20, 2020.

As a leading global medical technology company, BD focuses on improving health care delivery and diagnostics, enhancing safety, efficiency, and access worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
conferences
-
Rhea-AI Summary

BD (NYSE: BDX) announces a commitment of $7.8 million over three years to support the Helping Build Healthy Communities initiative, enhancing healthcare access for underserved populations. This funding will increase total investments to $22.6 million since 2013. The initiative, in collaboration with Direct Relief and NACHC, focuses on assisting community health centers, which serve nearly 30 million patients. The funds aim to boost innovative healthcare approaches, especially vital during the ongoing COVID-19 pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
Rhea-AI Summary

BD (Becton, Dickinson and Company) reported Q3 revenue of $3.855 billion, an 11.4% decrease year-over-year. Diluted EPS fell 35.8% to $0.97. Key segments showed mixed results: BD Medical revenue decreased 8.2%, BD Life Sciences dropped 10.1%, while BD Interventional saw a 20.3% decline. Despite challenges, BD noted strong demand for COVID-19 products and positive trends in healthcare procedures. Full-year revenue outlook is a 2.5% to 3.0% decrease, with adjusted EPS guidance between $9.80 and $10.00, reflecting a substantial decline from last year's figures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.4%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
none
-
Rhea-AI Summary

BD (Becton, Dickinson and Company) announced a $24 million investment from the U.S. Department of Defense and Health and Human Services to enhance U.S. manufacturing of the BD Veritor™ Solution for SARS-CoV-2. This investment aims to boost production capacity by 50%, enabling the company to produce over 12 million test kits monthly by February 2021. The BD Veritor™ Plus assay's performance includes 84% sensitivity and 100% specificity, making it a critical tool for rapid COVID-19 diagnosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
covid-19
Rhea-AI Summary

BD (Becton, Dickinson and Company) (NYSE: BDX) announced FDA approval for a pre-market approval supplement for its BD Onclarity™ HPV Assay. The approval expands genotype reporting capabilities to include types 31, 51, 52, 33/58, 35/39/68, and 56/59/66. This makes the assay the only FDA-approved tool to identify and report these genotypes individually, enhancing cervical cancer screening and risk assessment. The extended genotyping is vital for improved patient management, potentially reducing unnecessary treatments by offering precise risk stratification based on HPV types.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
Becton Dickinson & Co

NYSE:BDX

BDX Rankings

BDX Stock Data

58.70B
285.49M
0.56%
93.73%
1.02%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
FRANKLIN LAKES